A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature (2016) 3.18

Treatment of bipolar disorder. Lancet (2013) 2.93

Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology (2011) 2.79

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry (2012) 2.74

Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev (2012) 2.54

Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) (2014) 2.37

Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17

Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry (2013) 1.92

Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology (2011) 1.85

Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry (2011) 1.77

A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry (2012) 1.76

(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function. Anesthesiology (2014) 1.76

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology (2012) 1.74

A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats. Anesthesiology (2011) 1.72

A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry (2014) 1.69

Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation (2011) 1.56

Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol Psychiatry (2014) 1.54

To use or not to use: an update on licit and illicit ketamine use. Subst Abuse Rehabil (2011) 1.47

Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry (2012) 1.47

Translating glutamate: from pathophysiology to treatment. Sci Transl Med (2011) 1.42

A comment on Fond and colleagues' systematic review and meta-analysis of ketamine in the treatment of depressive disorders (Psychopharmacology 2014; Jul 20 [Epub ahead of print]). Psychopharmacology (Berl) (2014) 1.40

Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med (2014) 1.39

GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology (2013) 1.37

Induction of prolonged mania during ketamine therapy for reflex sympathetic dystrophy. Biol Psychiatry (2011) 1.32

Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol Psychiatry (2013) 1.31

Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology (2012) 1.31

Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry (2012) 1.29

Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology (2011) 1.28

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med (2016) 1.26

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol (2013) 1.25

Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin. J Psychiatry Neurosci (2013) 1.25

Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav (2011) 1.24

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 1.24

Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions. Proc Natl Acad Sci U S A (2015) 1.23

Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol (2015) 1.22

Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol (2014) 1.21

A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol (2012) 1.20

Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats. Biol Psychiatry (2013) 1.19

Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav (2011) 1.18

Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord (2014) 1.18

Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs (2012) 1.17

Is there anything really novel on the antidepressant horizon? Curr Psychiatry Rep (2012) 1.17

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry (2015) 1.17

Stereoselective and regiospecific hydroxylation of ketamine and norketamine. Xenobiotica (2012) 1.15

Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci (2014) 1.15

Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry (2014) 1.14

Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci (2013) 1.12

Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol (2012) 1.11

The role of ketamine in treatment-resistant depression: a systematic review. Curr Neuropharmacol (2014) 1.10

Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci (2011) 1.10

Human biomarkers of rapid antidepressant effects. Biol Psychiatry (2013) 1.09

Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res (2014) 1.09

Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry (2012) 1.09

Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.09

Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev (2013) 1.08

Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology (2013) 1.08

Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol (2014) 1.06

Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol (2012) 1.06

Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry (2012) 1.06

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci (2015) 1.04

Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One (2013) 1.04

N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants. Arch Gen Psychiatry (2010) 1.03

Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat (2013) 1.02

Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. J Psychopharmacol (2011) 1.02

A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci (2012) 1.02

Cell atrophy and loss in depression: reversal by antidepressant treatment. Curr Opin Cell Biol (2011) 1.01

Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry (2014) 1.00

Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) (2015) 1.00

Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression. Neuroscience (2012) 0.99

Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis (2015) 0.98

An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol (2011) 0.97

Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord (2012) 0.95

Antidepressant chronotherapeutics for bipolar depression. Dialogues Clin Neurosci (2012) 0.95

Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord (2013) 0.95

Rapid antidepressant effects: moving right along. Mol Psychiatry (2013) 0.93

BDNF - a key transducer of antidepressant effects. Neuropharmacology (2015) 0.93

Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J ECT (2012) 0.92

How does ketamine elicit a rapid antidepressant response? Curr Opin Pharmacol (2014) 0.92

A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks. Br J Pharmacol (2014) 0.91

Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol (2015) 0.91

Stress-induced changes of hippocampal NMDA receptors: modulation by duloxetine treatment. PLoS One (2012) 0.91

Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats. Psychopharmacology (Berl) (2014) 0.90

Acute D-serine treatment produces antidepressant-like effects in rodents. Int J Neuropsychopharmacol (2011) 0.90

Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med (2016) 0.89

D-serine as a gliotransmitter and its roles in brain development and disease. Front Cell Neurosci (2013) 0.89

The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci (2015) 0.88

New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs. Br J Clin Pharmacol (2016) 0.87

Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. Int J Neuropsychopharmacol (2014) 0.87

PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs (2014) 0.86

A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord (2012) 0.86

Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial. BMJ Open (2012) 0.86

Current status of ketamine and related compounds for depression. J Clin Psychiatry (2013) 0.86

Antidepressant mechanism of ketamine: perspective from preclinical studies. Front Neurosci (2015) 0.85

Dentate gyrus-CA3 glutamate release/NMDA transmission mediates behavioral despair and antidepressant-like responses to leptin. Mol Psychiatry (2014) 0.85

Sex Differences in Effects of Ketamine on Behavior, Spine Density, and Synaptic Proteins in Socially Isolated Rats. Biol Psychiatry (2016) 0.84

Serine enantiomers as diagnostic biomarkers for schizophrenia and bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2015) 0.84

Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade. Front Mol Neurosci (2014) 0.83

Characterization and modeling of intermittent locomotor dynamics in clock gene-deficient mice. PLoS One (2013) 0.83

Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine. Clin Psychopharmacol Neurosci (2014) 0.83

A rating scale for depression. J Neurol Neurosurg Psychiatry (1960) 90.89

A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry (1978) 25.54

The assessment of anxiety states by rating. Br J Med Psychol (1959) 24.58

Measurement of feelings using visual analogue scales. Proc R Soc Med (1969) 12.24

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84

Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 10.91

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88

Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry (2007) 8.11

Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07

Antidepressants and the risk of suicidal behaviors. JAMA (2004) 7.08

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci (1997) 5.30

Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry (1974) 4.76

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46

The definition and meaning of treatment-resistant depression. J Clin Psychiatry (2001) 3.98

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol (2008) 3.90

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol (2006) 3.77

Cross-national analysis of the associations among mental disorders and suicidal behavior: findings from the WHO World Mental Health Surveys. PLoS Med (2009) 3.38

Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress (1998) 3.07

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry (2002) 3.01

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry (2000) 2.92

Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry (2006) 2.68

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry (2005) 2.59

Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry (2004) 2.37

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol (1990) 1.82

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65

Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65

The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64

Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57

Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth (1985) 1.42

Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord (2008) 1.38

Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology (2009) 1.36

Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res (2006) 1.34

Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport (2001) 1.31

Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry (2006) 1.24

Bipolar disorder: from genes to behavior pathways. J Clin Invest (2009) 1.24

Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol Psychiatry (2003) 1.22

Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol (1994) 1.20

N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr Res (2006) 1.18

Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull (2002) 1.07

Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol (1993) 1.00

Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology (1997) 1.00

Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol Biochem Behav (1995) 1.00

Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. J Clin Psychopharmacol (2005) 0.94

Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry (2008) 0.91

Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol Biochem Behav (1993) 0.91

Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: a short-term, low dose, randomized, placebo-controlled study. J Clin Psychopharmacol (2008) 0.82

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59

Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46

International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord (2014) 4.10

The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry (2003) 3.00

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry (2012) 2.74

The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28

Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17

Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17

Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09

Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09

Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05

Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE (2004) 2.04

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry (2002) 2.01

The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97

The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94

Pathophysiology of primary spinal syringomyelia. J Neurosurg Spine (2012) 1.92

Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92

Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther (2009) 1.90

Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90

Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85

Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry (2002) 1.84

A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83

AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79

Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology (2008) 1.79

A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry (2012) 1.76

Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74

Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry (2003) 1.72

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71

An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71

Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71

Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry (2003) 1.68

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65

Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65

Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65

The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64

The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62

Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61

Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57

Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neuroimage (2005) 1.57

Effects of tryptophan depletion on serum levels of brain-derived neurotrophic factor in unmedicated patients with remitted depression and healthy subjects. Am J Psychiatry (2005) 1.55

Intraoperative infrared functional imaging of human brain. Ann Neurol (2003) 1.54

The Wnt signaling pathway in bipolar disorder. Neuroscientist (2002) 1.53

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51

Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg (2007) 1.51

Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry (2005) 1.51

Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry (2010) 1.51

The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep (2007) 1.50

Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. Am J Psychiatry (2005) 1.48

Validation of digital spiral analysis as outcome parameter for clinical trials in essential tremor. Mov Disord (2011) 1.47

Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry (2012) 1.47

Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord (2007) 1.46

Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci (2004) 1.45

Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry (2005) 1.44

Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry (2003) 1.44

Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry (2008) 1.42

Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42

Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology (2007) 1.42

Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2007) 1.41

Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology (2008) 1.41

In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology (2004) 1.41

Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med (2010) 1.41

Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry (2007) 1.40

Molecular effects of lithium. Mol Interv (2004) 1.39

Cerebral blood flow in immediate and sustained anxiety. J Neurosci (2007) 1.38